$1.12
+0.04 (+3.70%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SXTP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 expanded access · 2 with posted results
Held by 1 tracked-famous manager (CITADEL ADVISORS LLC) · FINRA short interest 1.5 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for BabesiosisNCT06207370Time to sustained clinical resolutionRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Tafenoquine · Other: Placebo | Babesiosis | 33 | 2027-03-01 | in 194 d | 2025-11-21 |
| B-FREE Chronic Babesiosis StudyNCT06656351Change in General FatigueOpen-label · Treatment | Phase 2 | Recruiting | Drug: Tafenoquine 100mg | Chronic Babesiosis | 40 | Feb 2027 | ≤ 193 d | 2025-11-21 |
| Tafenoquine in Patients With Mild to Moderate COVID-19NCT04533347results2025-01-07Number of Patients With Clinical Recovery of COVID-19 Symptoms on Day 14Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Tafenoquine Oral Tablet, Placebo | COVID 19 Disease | 86 | 2022-06-30actual | — | 2025-01-07 |
| Long-Term Safety Study of TafenoquineNCT03320174results2026-04-17Serious Ophthalmic Safety EventRandomized · Quadruple-masked · PreventionStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Tafenoquine · Other: Placebo | Healthy Volunteers | 600 | 2021-07-13actual | — | 2026-04-17 |
| Expanded Use in Persistent (B. Microti) BabesiosisNCT06478641expanded access | — | Available | Drug: Tafenoquine | Persistent Babesiosis | — | — | — | 2025-11-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19